NeurologyLive® Friday 5 — September 13, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, August 2024: Approvals, Designations, and Clearances

The FDA was busy in August 2024, making a number of decisions on potential new therapeutic agents including granting approvals, designations, and clearances.

2: Beyond the Virus: Long COVID’s Neurological Toll

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

3: Understanding Smoldering Disease in MS Beyond Focal Inflammatory Activity: Antonio Scalfari, MD, PhD

The consultant neurologist at Imperial College Healthcare Trust talked about how smoldering disease in multiple sclerosis encompasses disease progression independent of relapsing activity, thus broadening the scope beyond traditional measures. [WATCH TIME: 4 minutes]

4: NeuroVoices: Tom Fuchs, MD, PhD, on Development and Clinical Utility of the DAAE Score for MS Progression Prediction

The postdoctoral researcher at Amsterdam University Medical Center talked about a tool that helps assess the likelihood of transitioning to secondary progressive multiple sclerosis, allowing clinicians to make informed treatment decisions in a timely manner.

5: Reaching a Consensus About Care Expectations, Comorbidities of SCN8A-Related Disorders: Gabi Conecker; JayEtta Hecker

Representatives from the SCN8A Alliance provided clinical insight on a recently published paper that captured information on the estimated frequency, severity, and prognosis of comorbidities in SCN8A-related disorder phenotypes. [WATCH TIME: 5 minutes]